Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COGNITO-MB neurocognitive comparison in low-risk SHH medulloblastoma
NL-OMON58746Phase 3Not yet recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jul 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin in medulloblastoma (2 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Full-Scale Intelligence Quotient. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
carboplatin
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NL-OMON58746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58746.